MKC 253
MKC253 is a formulation of GLP-1 (glucagon-like peptide) on Technosphere® particles that is delivered using the Company's proprietary inhaler. In initial clinical studies, MKC253 has shown a lack of characteristic adverse events frequently seen with long- acting forms
of GLP-1. (e.g. nausea)
Our hypothesis at present is that delivery of active GLP-1 to the arterial circulation via the lung avoids much of the degradation by dipeptidyl peptidase-4 that occurs prior to the compound reaching the primary site of endocrine action. Thus, we may be able to achieve a different response profile with pulmonary MCK253 than that seen with subcutaneous or intravenous administration of GLP-1. Moreover, the pulsatile administration of MKC253 achieved with our proprietary Technosphere® delivery technology appears to avoid the dose-limiting vomiting characteristically associated with GLP-1 and replaces a physiological response lost in patients with diabetes that cannot be replicated by other forms of GLP-1.
We believe that MKC253 represents a novel approach to the use of GLP-1 as a prandial therapy for diabetes either alone, or in combination with prandial insulin.
